الفهرس Only 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
In this study conducted on sixty - seven Egyptian patients newly diagnosed as having mature B - cell lymphoproliferative disorder, we investigated the expression of CD 200 on their lymphoma cells and found that CD 200 was consistently expressed on chronic lymphocytic leukemia and hairy cell leukemia B cells clone, while it was negatively expressed in mantle cell lymphoma patients and showed a heterogeneous expression in other CD5 positive Non - Hodgkin lymphomas. We also found that CD 200 high expression ({u2265} 50%) was associated with several adverse prognostic factors although more cases were needed for confirmation. We concluded that the enrollment of CD200 as a routine investigatory marker in the flowcytometry panel of chronic lympho-proliferative disorders could be of high value in distinguishing between their members especially between CLL and MCL and in atypical CLL cases or those with unusual immunophenotype. In addition we found that CD 200 expression in CLL may be of prognostic value